Last reviewed · How we verify
NCT01280604
Effects of Fenofibrate 160mg to 54mg Conversion on Triglyceride Levels in Patients on Statin Therapy
NA trial testing Fenofibrate 54mg in Hyperlipidemias in 66 participants. Completed in 1 January 2013.
1 January 2013
Quick facts
| Lead sponsor | Kaiser Permanente |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 66 |
| Start date | 1 October 2010 |
| Primary completion | 1 January 2013 |
| Estimated completion | 1 January 2013 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Fenofibrate 54mg — full drug profile →
Conditions studied
- Hyperlipidemias — all drugs for Hyperlipidemias →
Sponsor
Kaiser Permanente — full company profile →
Who can join
18 and older, any sex, with Hyperlipidemias. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Triglyceride Levels
Time frame: 6-10 weeks
Triglyceride levels will be assessed in study participants 6-10 weeks after entry into study.
Sponsor's own description
The primary objective of this randomized trial is to measure the impact of converting patients on statin therapy from fenofibrate 160mg to 54mg per day compared to patients who continue fenofibrate 160mg per day for triglycerides.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT01280604
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hyperlipidemias
Currently open trials in the same condition.
- NCT06903897 — Social Needs Screening and Chronic Diseases Study (WE CARE) · NA · recruiting
- NCT06049420 — Lifestyle Medicine: Establishing Clinical Approaches to Chronic Disease for Rural Patients · NA · recruiting
- NCT06461273 — Food is Medicine vs Lifestyle Medicine For Cardiovascular Kidney Metabolic (CKM) Syndrome · NA · active not recruiting
- NCT06094491 — Virtual Diabetes Group Visits Across Health Systems · Phase 2 · active not recruiting
- NCT06055036 — Black Impact: The Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention · NA · recruiting
Other Kaiser Permanente trials
Trials by the same sponsor.
- NCT07522645 — Adherence to Dyslipidemia Therapy: Harnessing Evidence From Randomized Evaluations in AtheroSclerotic CardioVascular Dis · NA · not yet recruiting
- NCT07474038 — AI-Supported Cognitive Rehabilitation for Older Adults With Mild Cognitive Impairment · NA · enrolling by invitation
- NCT07467668 — Infusing Needed Iron to Target Insufficiency in Adults Treated for Evidence of Heart Failure · NA · not yet recruiting
- NCT07216859 — Screening Cardiometabolic Opportunities Using Transformative Echocardiography Artificial Intelligence (SCOUT Echo-AI) · NA · not yet recruiting
- NCT07264062 — MetSense Pilot and Feasibility · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01280604 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Kaiser Permanente
- Last refreshed: 4 June 2015
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01280604.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing